Retroperitoneal and Mesenteric Liposarcomas.

Surg Oncol Clin N Am

Department of Surgical Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanlaan 121, Amsterdam 1066 CX, the Netherlands. Electronic address:

Published: July 2022

Retroperitoneal liposarcomas are a rare entity and are comprised mostly of the well-differentiated and dedifferentiated subtypes. Eight-year survival ranges from 30% to 80% depending on histologic subtype and grade. Surgery is the cornerstone of treatment and compartment resection is the current standard. Mesenteric liposarcomas are extremely rare and comprise more high-grade lesions, with poorer prognosis of 50% 5-year overall survival. They are managed with a similar aggressive surgical approach. This review presents the current management of retroperitoneal and mesenteric liposarcomas.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.soc.2022.03.005DOI Listing

Publication Analysis

Top Keywords

mesenteric liposarcomas
12
retroperitoneal mesenteric
8
liposarcomas
4
liposarcomas retroperitoneal
4
retroperitoneal liposarcomas
4
liposarcomas rare
4
rare entity
4
entity comprised
4
comprised well-differentiated
4
well-differentiated dedifferentiated
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!